Suzzan8@hotmail.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tucker Carlson is doing therapeutics to treat covid next week. I sent some links on IPIX via messenger to him. I know there was a sticky for a very good over view of brilicidin but I can’t find it anymore. If anyone has that link can you send that and any other good sources to his account?
I would think if they did, they wouldn’t be presenting at the conference?
Email out
My fellow IPIX shareholders,
I’d like to take a moment to share with you an extremely interesting article published on September 18, 2020, in The New Yorker, which speaks to our excitement in developing Brilacidin, our flagship defensin mimetic.
The article, “Scientists Advance on One of Technology’s Holy Grails,” goes into extensive detail regarding the accelerating trend in designing proteins for treating notoriously difficult maladies, including COVID-19 and cancer, in addition to other non-medical applications. William DeGrado, who recently joined the Company as a Scientific Advisor, is cited given his seminal work in this area. The crux of the article is the importance of, and opportunity in developing, novel therapies by designing and manufacturing variations of innate proteins to fill gaps in medicine today, and potentially to do so more efficiently than current drug discovery efforts.
Brilacidin is designed to mimic human proteins that serve as the front line of defense for the immune system. As we have theorized since our acquisition of Brilacidin – and subsequently supported by successful results in clinical trials in supportive cancer care, bacterial infections, and inflammatory bowel disease – the drug has exhibited robust therapeutic properties, with platform potential across numerous indications.
I encourage all our shareholders to read the highly informative article available at https://www.newyorker.com/tech/annals-of-technology/the-promise-of-designer-protein-in-the-fight-against-covid-19
Me too. My break even is $1.90 I have friends that loaded up at the $4 point.
Exactly and I’d love to have that option.
Thank you Karin. That’s all I wanted to know. I’m grateful for urgent care as well. I have a busy week and I didn’t have time to go to my regular doctor. It wasn’t serious I just needed to be seen. Thank you for the information. And thank you for not personally attacking me and acting like an adult. I’ll drop that info off for him.
I wonder if that’s what he was talking about and just jumped to his own conclusions. Thank you for finding that. I thought if it was something big it would have popped up somewhere. Thank you for finding that. Much appreciated.
I’m just asking a question that’s all. I thought someone might want to look into it as he seemed to know the trial and drug. This was during a discussion that I might end up in the hospital if Leviquin quits working for me. I don’t have the time or energy to spend responding to rude arrogant posters. This wasn’t meant to be a discussion on my ethics. I hoped someone could look into it if not nothing to see here.
No I did not and I certainly won’t post anything I hear again on this board. It was a valid question with a sincere attempt to see if anyone had any information on it. No worries won’t happen again.
No I don’t believe that at all. But since my doctor said that I thought someone might want to see if it’s factual. For all I know he’s confused and we aren’t talking about the same drug. I’m just looking for help from someone who has the ability to research it. I don’t know how he could know that quite frankly.
It just seemed odd to me that he’d know so much about the trial data. I didn’t ask how he found out but he seemed really knowledgeable about antibiotics in general. That’s why I put it out there to see if it was even possible to know that. I’m still buying as well. This isn’t a one trick pony. But I thought someone might know how to find out if it’s true or not. I could email Leo but I thought someone here might know how to research it.
I’m hoping he’s wrong or confused about the drug. Thats why I thought one of the brains on here could maybe see if it’s correct. I wouldn’t even know where to start to find out if there was a problem with liver enzymes.
Urgent care but we have a pretty good one here.
That’s why I’m asking. He said I was on the last antibiotic I can get and then I will have to go to the hospital. I mentioned Brilacidin and that I was hoping that one would make it to market. He said he was familiar with the trials for it and it might not make it to market. I have over $100k invested so I was quietly freaking. That’s why I ask if anyone knew anything about this and could he maybe be confusing it with another drug. I’m not a scientist but I’m not an idiot either. Don’t be so quick to judge. I’m hoping more knowledgeable people on this board can shed some light on this for me. My average is about 1.90 so I certainly don’t want to do anything to harm the stock I am just looking for info from more knowledgeable investors. We do have a brain trust here that knows more than I do and how to research what he told me.
I just got out of my doctors for sinus infection. I am on the last antibiotic that works for me. I asked him about Brilacidin and he was familiar with the drug. His remarks were that we may not get that one because it’s having safety issues in the trials because it’s damaging the liver and failing enzyme tests. Does anyone know if this is true? Maybe he was confusing it with another trial? Maybe it’s not that big a deal? Can anyone with better medical research skills check on this and see if it’s accurate?
Innovation Pharmaceuticals Provides Corporate Update Highlighting Business Development and Clinical Pipeline Priorities
View it in your browser.
Innovation Pharmaceuticals Provides Corporate Update Highlighting Business Development and Clinical Pipeline Priorities
BEVERLY, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update highlighting business development and clinical pipeline priorities across its first-in-class drug candidates, Brilacidin, Prurisol and Kevetrin.
“A successful End-of-Phase 2 FDA meeting for our Brilacidin-Oral Mucositis asset, or positive results from our Phase 2b Prurisol trial in psoriasis—either outcome we believe would open up enormous possibilities for our shareholders,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We look forward to updating shareholders on these, and other company developments, as we continue to lay a strong scientific foundation upon which future successes can be built.”
Corporate priorities, and upcoming events, include:
Convening the End-of-Phase 2 meeting with the Food and Drug Administration (FDA) to discuss the expedited development of Brilacidin-Oral Mucositis. The meeting, scheduled for later this quarter, helps align with the FDA on clinical trial design and other program requirements.
Analyzing Prurisol topline results in Psoriasis once full payment can be made to the Contract Research Organization (CRO) based on amounts owed, which were, in part, more than budgeted due to significant cost overruns. A partial payment was recently made, with additional payments planned.
Selecting a CRO to complete the necessary remaining bridging toxicology work, approximately half of which has been completed, toward developing Kevetrin (our p53-modulating anti-cancer drug) in oral formulation and commencing its next clinical trial. As Kevetrin is not cytotoxic, the possibility exists for an oral version of Kevetrin to commence a Phase 1/1b study in healthy subjects, followed by a Phase 2 study—shortening the development timeline significantly.
Continuing to advance partnership discussions, with our primary objective to complete licensing deals that provide access to non-dilutive capital to move our clinical assets forward in the most expeditious and cost-effective manner.
Manufacturing Brilacidin final drug substance/drug product for a future, and potentially pivotal, Oral Mucositis clinical trial and, more broadly, for the bulk production of commercial-grade drug supply. The Company has already paid contracted vendors over $1 million toward project completion.
Presenting a scientific poster on Brilacidin for Inflammatory Bowel Disease (IBD) at the “IBD Innovate 2018” conference sponsored in part by the Crohn’s & Colitis Foundation and held in New York City. The poster will be available in the Events and Presentations section of the Company website on November 13, 2018.
Expanding the Company’s Intellectual Property when appropriate, as was recently completed in relation to Brilacidin—the U.S. Patent & Trademark Office announcing allowances directed to oral, buccal, and sublingual pharmaceutical compositions of the drug.
Developing an oral formulation of Brilacidin to treat more extensive forms of IBD (e.g., Ulcerative Colitis and Crohn’s Disease) and a topical formulation of Brilacidin for Inflammation and Immunology (I&I) conditions (e.g., Atopic Dermatitis and Acne), in preparation for subsequent clinical trials.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infections. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations, and has successfully completed a Phase 2 trial in ovarian cancer. Prurisol, an oral psoriasis drug candidate acting through immune modulation and PRINS reduction, has now completed a Phase 2b trial and is awaiting statistical analysis. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Copyright © 2018 Innovation Pharmaceuticals, All rights reserved.
You requested to receive email alerts about Innovation Pharmaceuticals at our website http://www.ipharminc.com/
Our mailing address is:
Innovation Pharmaceuticals
100 Cummings Center, Suite 151-B
Beverly, MA 01915
Add us to your address book
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences
I agree with you. Just read of a person who transplanted four organs and all the healthy recipients ending up getting cancer. We know so very little about this. My mother died of breast cancer as well.
I wonder if Biohedge dumped his interest?
No it’s not odd. People like to keep their options open and lots of professional people don’t spend much time updating their page. Especially when they aren’t looking for a job. She probably is a bit preoccupied with her demanding job at IPIX.
Her name is listed under senior mgmt on the ipix webpage.
Innovation Pharmaceuticals Signs Drug Supply Contract with Evonik to Bulk Produce Commercial-Grade Brilacidin
https://finance.yahoo.com/news/innovation-pharmaceuticals-signs-drug-supply-120000504.html
Do companies produce drugs that have no marketability?
I have that email but I’d have to go through my deleted mail to find the date.
Did you try (978) 921-4125?
This is old and may have been shared already but it was interesting article.
https://ibdnewstoday.com/2017/06/27/all-12-bowel-disease-patients-wrap-up-brilacidin-treatment-in-phase-2-clinical-trial/
Is anyone planning to attend the conferences???
Your comments and insight are appreciated. Thank you.
Nice presentation good info for new eyes.
Leo said several years ago he doesn't read any of the boards. I doubt he's aware of what's going on here unless he has found more free time to hang around here.
Yikes! I'm getting panicked hate mail from people I got into this stock! I'm so disappointed but I'm encouraging them to hold like me. I have so much money in this stock if it doesn't get back on track I'm going to feel really stupid and start driving a beater!
I thought it said $100,000K?
Remember they are still recruiting.
Strong Bio has new piece on CTIX on stinking alpha, I mean seeking alpha. I'll wait for the brain trust members to analyze. Thanks in advance.
Don't know yet if he has it bad enough to qualify but his dermatologist had never heard of it and is going to look at the study guidelines etc. He was very interested in the study.
I know someone who is trying to get into the P2b trial and they are still recruiting.
Me too, go big or go home.
I have children, filthy rich would go further for me! ????
Don't feel bad, you're not alone! My eggs are sitting right next to yours in the same basket! I still see a light at the end of the tunnel and if it ends up being another train I will have made the second biggest mistake of my life! I hope I'm right in holding long term. I've been in for almost four years.